SynergEyes, Inc., founded in 2001, stands at the forefront of specialty contact lenses innovation, particularly for patients with Normal and Irregular Corneal Conditions. As a leading player in the Health Care, Manufacturing, and Medical Devices sectors, the company operates out of the United States. Their commitment to advanced ocular solutions is exemplified by their comprehensive portfolio of technologically-advanced contact lenses.
Through continuous innovation, SynergEyes has expanded its product lineup since introducing the first generation of hybrid lenses in 2005. The latest addition, SynergEyes iD, offers a bespoke lens solution ideal for conditions like astigmatism, presbyopia, hyperopia, and myopia. Their Continuum of Care features the UltraHealth and SynergEyes VSTM scleral lenses to address various stages of Keratoconus.
Their strategy involves partnering with independent eye care professionals to enhance patient outcomes. The company last secured a $3.50M Early VC investment on 01 February 2017, indicating a stable financial platform to support future growth and innovation.